This book is about asymmetric "David & Goliath" partnerships in pharmaceutical R&D--bilateral arrangements in which one partner is a smaller bioscience or academic organization (David) and the other a large multinational corporation (Goliath).
The new distributed model of R&D seamlessly blends external partnerships with in-house efforts to generate innovative medicin.
The past decade has seen a paradigm shift in how medicines and other therapies are discovered, developed and commercialized.
This book is about asymmetric "David & Goliath" partnerships in pharmaceutical R&D--bilateral arrangements in which one partner is a smaller bioscience or academic organization (David) and the other a large multinational corporation (Goliath)
